Navigation Links
Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
Date:10/30/2007

Conference Call and Webcast to Follow

ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced it will release results for the quarter ended September 30, 2007, on Thursday, November 8, 2007, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results and other corporate developments at 10:30 AM ET on Thursday, November 8, 2007. Also participating on the call will be Steven A. Shallcross, Senior Vice President and CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.

The teleconference dial-in numbers are as follows:

Domestic callers 1-866-578-5801

International callers 1-617-213-8058

The conference call will be broadcast simultaneously and archived on the Company's Web site, http://www.vandapharma.com. Investors should go to the Web site at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, November 8, 2007, beginning at 12:30 PM ET and will be accessible until Thursday, November 15, 2007, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 60186931.

About Vanda Pharmaceuticals Inc.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder, and has recently submitted an NDA to the FDA for the treatment of schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for sleep disorders. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:

Steven A. Shallcross

Senior Vice President & CFO

Vanda Pharmaceuticals Inc.

(240) 599-4500

steven.shallcross@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the ... national TV host Tom Seay and his production crew. Tom Seay’s program “Best ... around the world. Saddle Sidekicks will be featured on April 6, 2017. After ...
(Date:2/22/2017)... ... 2017 , ... The Centers for Medicare & Medicaid Services ... Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate in the ... of 2015 (MACRA). , This technical assistance, authorized and funded under MACRA, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... 72 percent of those report that family members or friends have also commented ... suffer from hearing loss wear hearing aids. One reason, suggested by 89 percent ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS ... from combat-related PTSD. , Established in 1977, our organization was at the forefront ... military returning to civilian life were evident and served as the catalyst for ...
(Date:2/22/2017)... ... 22, 2017 , ... Apptricity® Corporation, a leading global provider ... today announced that Keppel Corporation has selected Apptricity Travel and Expense Management integrated ... are excited to announce the partnership between Keppel and Apptricity for our Global ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... -- Andre, DiMino, CEO of ADM Tronics Unlimited, Inc. (OTCQB: ... and products, commented on ADMT,s third quarter fiscal year ... the Company,s quarterly report on Form 10Q available at ... stated "During the quarter ended December 31, 2016 we ... portion of our engineering efforts into the development of ...
(Date:2/22/2017)... VANCOUVER, Feb. 22, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) ... for the quarter and full fiscal year ended December 31, ... ... the Company,s audited financial statements and management discussion and analysis ... have been filed on SEDAR and are available at ...
(Date:2/22/2017)... , Feb. 22, 2017 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... host its Fourth Quarter 2016 investor conference call and webcast ... The call will cover an update on Merrimack,s ... and full year 2016 financial results. A press release detailing ... issued the morning of Wednesday, March 1. Investors and the ...
Breaking Medicine Technology: